Anti-phospholipid syndrome associated with schizophrenia description of five patients and review of the literature

scientific article published on 19 January 2017

Anti-phospholipid syndrome associated with schizophrenia description of five patients and review of the literature is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S12026-017-8895-1
P698PubMed publication ID28102512

P2093author name stringAiman Natur
Levy Yair
Pikman Regina
Rotman Pnina
P2860cites workThe role of inflammation in schizophreniaQ26779719
Dysfunction in the coagulation system and schizophreniaQ28068412
Association of schizophrenia and autoimmune diseases: linkage of Danish national registersQ28300105
Neurological involvement in antiphospholipid antibodies syndrome (APS).Q33335118
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patientsQ33341941
Inferior vena cava thrombosis in a patient with chlorpromazin-induced anticardiolipin antibodiesQ77799413
Expression of anti-cardiolipin antibodies and inflammatory associated factors in patients with schizophreniaQ84325188
[Extensive cutaneous necrosis as an initial manifestation of secondary antiphospholipid syndrome (APS)]Q84741497
[Psychosis as debut of antiphospholipid syndrome]Q95383968
Paediatric case report: primary antiphospholipid syndrome presented with non-thrombotic neurological picture psychosis; treat by antidepressants alone?Q33389062
Primary antiphospholipid antibody syndrome presenting with encephalopathy, psychosis and seizuresQ33396284
High association of anticardiolipin antibodies with psychosisQ33501832
Differences in the natural autoantibody patterns of patients with schizophrenia and normal individualsQ33921689
Acute psychosis due to non-paraneoplastic anti-NMDA-receptor encephalitis in a teenage girl: Case reportQ34504991
Antiphospholipid antibodies in blood and cerebrospinal fluids of patients with psychosisQ34687562
Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studiesQ35189295
Anti-N-methyl-d-aspartate receptor encephalitis in a patient with a 7-year history of being diagnosed as schizophrenia: complexities in diagnosis and treatmentQ35746924
Schizophrenia and rheumatoid arthritis: a reviewQ36043077
Coeliac disease and schizophrenia: population based case control study with linkage of Danish national registersQ36234994
Catatonic Syndrome in Anti-NMDA Receptor EncephalitisQ36764529
Venous thromboembolism in recipients of antipsychotics: incidence, mechanisms and managementQ38021516
Updating the mild encephalitis hypothesis of schizophreniaQ38024169
Risk of venous thromboembolism during treatment with antipsychotic agentsQ38068538
A systematic, quantitative review of blood autoantibodies in schizophreniaQ38129587
The epidemiologic evidence linking autoimmune diseases and psychosis.Q38160515
Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register studyQ38435398
NMDA Receptor Internalization by Autoantibodies: A Reversible Mechanism Underlying Psychosis?Q38821460
Early neuropsychiatric involvement in antiphospholipid syndromeQ40291856
Autoimmunity in schizophrenia: a review of recent findingsQ40785380
Infection and autoimmunity as etiologic factors in schizophrenia: a review and reappraisalQ40821139
Increased prevalence of antibrain antibodies in the sera from schizophrenic patientsQ41419057
Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: absence of thrombosisQ42208790
Prevalence of antiphospholipid antibodies in psychiatric patients users and non-users of antipsychoticsQ43837495
Family history of autoimmune diseases in psychosisQ44254596
Elevated IGG and IGM anticardiolipin antibodies in a subgroup of medicated and unmedicated schizophrenic patientsQ46112223
Anti-phospholipid antibodies in cerebrospinal fluid but not serum from a boy with psychosisQ46255845
Higher serum clozapine level is associated with increased antiphospholipid antibodies in schizophrenia patientsQ46270431
Anti-brain autoantibodies in the serum of schizophrenic patients: a case-control studyQ46273128
Psychiatric remission with warfarin: Should psychosis be addressed as plasminogen activator imbalance?Q48267117
Psychosis leading to the diagnosis of unrecognized systemic lupus erythematosus: a case reportQ48301096
Familial thyroid disease and delayed language development in first admission patients with schizophreniaQ48693258
Prevalence of autoimmune diseases in in-patients with schizophrenia: nationwide population-based studyQ48710157
A 16-year-old girl with anti-NMDA-receptor encephalitis and family history of psychotic disordersQ50310741
Markers of low activity of tissue plasminogen activator/plasmin are prevalent in schizophrenia patients.Q50634463
Psychiatric manifestations as a primary symptom in antiphospholipid syndrome.Q51773681
Genetic association of the HLA DRB1 gene locus on chromosome 6p21.3 with schizophreniaQ58143653
Psychosis and catatonia as a first presentation of antiphospholipid syndromeQ60632115
Obstetric complications and autoantibodies in schizophreniaQ71633467
Anticardiolipin antibodies are elevated in drug-free, multiply affected families with schizophreniaQ72303293
Anticardiolipin antibodies in a sample of chronic schizophrenics receiving neuroleptic therapyQ72669795
The antiphospholipid syndrome and psychosisQ72850832
The antiphospholipid syndromeQ77739053
P433issue2
P407language of work or nameEnglishQ1860
P921main subjectschizophreniaQ41112
P304page(s)438-446
P577publication date2017-01-19
P1433published inImmunologic ResearchQ15754981
P1476titleAnti-phospholipid syndrome associated with schizophrenia description of five patients and review of the literature
P478volume65

Search more.